Last reviewed · How we verify

propofol (drug)

B. Braun Melsungen AG · Phase 3 active Small molecule Under review Quality 0/100

propofol (drug) is a GABA receptor agonist Small molecule drug developed by B. Braun Melsungen AG. It is currently in Phase 3 development for General anesthesia, Sedation for mechanical ventilation, Sedation for diagnostic or surgical procedures.

Propofol is a short-acting sedative-hypnotic agent that acts on the central nervous system to induce and maintain anesthesia.

Propofol is a small molecule that acts as a positive allosteric modulator of the GABA-A receptor, an anion channel. It is used in medical settings for conditions such as sedation, anesthesia, and spinal anesthesia, among others.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namepropofol (drug)
SponsorB. Braun Melsungen AG
Drug classGABA receptor agonist
TargetGABA_A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Propofol works by enhancing the inhibitory neurotransmission mediated by GABA (gamma-aminobutyric acid), a major inhibitory neurotransmitter in the brain. This results in a decrease in neuronal excitability, leading to sedation, hypnosis, and amnesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about propofol (drug)

What is propofol (drug)?

propofol (drug) is a GABA receptor agonist drug developed by B. Braun Melsungen AG, indicated for General anesthesia, Sedation for mechanical ventilation, Sedation for diagnostic or surgical procedures.

How does propofol (drug) work?

Propofol is a short-acting sedative-hypnotic agent that acts on the central nervous system to induce and maintain anesthesia.

What is propofol (drug) used for?

propofol (drug) is indicated for General anesthesia, Sedation for mechanical ventilation, Sedation for diagnostic or surgical procedures.

Who makes propofol (drug)?

propofol (drug) is developed by B. Braun Melsungen AG (see full B. Braun Melsungen AG pipeline at /company/b-braun-melsungen-ag).

What drug class is propofol (drug) in?

propofol (drug) belongs to the GABA receptor agonist class. See all GABA receptor agonist drugs at /class/gaba-receptor-agonist.

What development phase is propofol (drug) in?

propofol (drug) is in Phase 3.

What are the side effects of propofol (drug)?

Common side effects of propofol (drug) include Respiratory depression, Hypotension, Bradycardia, Nausea and vomiting, Headache, Dizziness.

What does propofol (drug) target?

propofol (drug) targets GABA_A receptor and is a GABA receptor agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing